Primrose syndrome (MONDO:0009798; OMIM 259050) is a rare autosomal dominant multisystem neurodevelopmental disorder caused by de novo heterozygous pathogenic variants in ZBTB20, a BTB-zinc finger transcriptional repressor. It is characterized by macrocephaly, hypotonia, developmental delay and intellectual disability with expressive speech delay, autistic and behavioral features, and a recognizable facial gestalt (frontal bossing, deeply set eyes, ptosis, downslanting palpebral fissures, large ears). A hallmark progressive somatic component (calcification of the external ear cartilage, cystic bone lesions, distal muscle wasting, and joint contractures) typically emerges between 10 and 16 years of age. Additional features include sensorineural hearing loss, cataract, disturbed glucose metabolism with insulin-resistant diabetes, hypothyroidism, anemia, and elevated serum alpha-fetoprotein. ZBTB20 dysfunction (often with a dominant-negative impact on the wild-type protein) dysregulates transcriptional programs controlling neurodevelopment, somatic growth, and energy metabolism.
Ask a research question about Primrose Syndrome. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
Conditions with similar clinical presentations that must be differentiated from Primrose Syndrome:
name: Primrose Syndrome
creation_date: "2026-06-04T12:00:00Z"
category: Mendelian
synonyms:
- PRIMS
- intellectual disability-cataracts-calcified pinnae-myopathy syndrome
description: >-
Primrose syndrome (MONDO:0009798; OMIM 259050) is a rare autosomal dominant
multisystem neurodevelopmental disorder caused by de novo heterozygous
pathogenic variants in ZBTB20, a BTB-zinc finger transcriptional repressor.
It is characterized by macrocephaly, hypotonia, developmental delay and
intellectual disability with expressive speech delay, autistic and behavioral
features, and a recognizable facial gestalt (frontal bossing, deeply set
eyes, ptosis, downslanting palpebral fissures, large ears). A hallmark
progressive somatic component (calcification of the external ear cartilage,
cystic bone lesions, distal muscle wasting, and joint contractures) typically
emerges between 10 and 16 years of age. Additional features include
sensorineural hearing loss, cataract, disturbed glucose metabolism with
insulin-resistant diabetes, hypothyroidism, anemia, and elevated serum
alpha-fetoprotein. ZBTB20 dysfunction (often with a dominant-negative impact
on the wild-type protein) dysregulates transcriptional programs controlling
neurodevelopment, somatic growth, and energy metabolism.
disease_term:
preferred_term: Primrose Syndrome
term:
id: MONDO:0009798
label: Primrose syndrome
parents:
- Syndromic Intellectual Disability
- Overgrowth Syndrome
references:
- reference: PMID:33956417
title: "Primrose Syndrome."
tags:
- GeneReviews
- reference: PMID:32266967
title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
- reference: PMID:25017102
title: "Mutations in ZBTB20 cause Primrose syndrome."
- reference: PMID:32071410
title: "Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20."
- reference: PMID:29737001
title: "Clinical and functional characterization of two novel ZBTB20 mutations causing Primrose syndrome."
- reference: PMID:30281617
title: "Neurodevelopmental disorder-associated ZBTB20 gene variants affect dendritic and synaptic structure."
inheritance:
- name: Autosomal dominant
inheritance_term:
preferred_term: Autosomal dominant inheritance
term:
id: HP:0000006
label: Autosomal dominant inheritance
description: >-
Primrose syndrome is an autosomal dominant disorder. Essentially all
reported probands whose parents have undergone molecular testing carry a
de novo ZBTB20 pathogenic variant; familial transmission has not been
reported.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome is an autosomal dominant disorder. All probands
reported to date with Primrose syndrome whose parents have undergone
molecular genetic testing have the disorder as a result of a de novo
ZBTB20 pathogenic variant.
explanation: >-
GeneReviews establishes autosomal dominant inheritance with a de novo
origin in all probands tested to date.
pathophysiology:
- name: ZBTB20 Transcriptional Repressor Dysfunction
description: >-
ZBTB20 is a BTB-zinc finger (BTB-ZF) transcriptional repressor with an
N-terminal BTB domain mediating protein-protein interactions and five
C-terminal C2H2 zinc fingers mediating sequence-specific DNA binding to
promoters of target genes. Most Primrose syndrome variants are de novo
missense changes affecting the first and second zinc-finger motifs, which
disrupt DNA binding. Functional studies show that both missense and
truncating Primrose-causing variants exert a dominant-negative impact on
wild-type ZBTB20, interfering with normal transcriptional repression and
dysregulating downstream developmental, growth, and metabolic gene programs.
cell_types:
- preferred_term: Pyramidal neuron
term:
id: CL:0000598
label: pyramidal neuron
biological_processes:
- preferred_term: Negative regulation of transcription by RNA polymerase II
term:
id: GO:0000122
label: negative regulation of transcription by RNA polymerase II
modifier: DECREASED
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The protein is a member of the broad complex tramtrack bric‐a‐brac (BTB)
zinc‐finger (ZnF) family and is characterized by an N‐terminal BTB domain
that is involved in protein‐protein interaction, and five C2H2 zinc
fingers at the C‐terminus mediating protein binding to regulatory sites
within promoters of target genes.
explanation: >-
Describes the molecular architecture of ZBTB20 as a BTB-ZF transcriptional
repressor binding promoter regulatory sites.
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
all ZBTB20 variants causing PS have been missense variants that affect
amino acid residues in the first and second ZnF motifs.
explanation: >-
Localizes the recurrent Primrose-causing missense variants to the first
and second zinc-finger DNA-binding motifs.
- reference: PMID:29737001
reference_title: "Clinical and functional characterization of two novel ZBTB20 mutations causing Primrose syndrome."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Our data document that both mutations have dominant negative impact on
wild-type ZBTB20, providing further evidence of the specific behavior of
PS-causing mutations on ZBTB20 function.
explanation: >-
Functional assays demonstrate a dominant-negative mechanism for both a
truncating and a zinc-finger missense Primrose variant.
downstream:
- target: Dysregulated Neurodevelopmental Gene Expression
description: >-
ZBTB20 transcriptional dysfunction dysregulates neurodevelopmental gene
programs.
- target: Disturbed Growth and Energy Metabolism
description: >-
ZBTB20 transcriptional dysfunction dysregulates growth and metabolic gene
programs.
- name: Dysregulated Neurodevelopmental Gene Expression
description: >-
ZBTB20 is a key regulator of neurogenesis, cortical lamination, and
hippocampal development. Neurodevelopmental-disorder-associated ZBTB20
variants alter dendritic spine morphology, dendritic arborization, and
dendritic length in cultured cortical pyramidal neurons, providing a
plausible cellular substrate for the intellectual disability, autistic
behavior, and behavioral phenotype of Primrose syndrome. Brain MRI commonly
shows corpus callosum anomalies, particularly in patients with missense
variants.
cell_types:
- preferred_term: Cortical pyramidal neuron
term:
id: CL:0000598
label: pyramidal neuron
- preferred_term: Hippocampal neuron
term:
id: CL:0002608
label: hippocampal neuron
biological_processes:
- preferred_term: Neurogenesis
term:
id: GO:0022008
label: neurogenesis
modifier: ABNORMAL
- preferred_term: Negative regulation of neuron differentiation
term:
id: GO:0045665
label: negative regulation of neuron differentiation
modifier: ABNORMAL
evidence:
- reference: PMID:30281617
reference_title: "Neurodevelopmental disorder-associated ZBTB20 gene variants affect dendritic and synaptic structure."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
defects of ZBTB20, a BTB and zinc finger domain containing transcriptional
repressor, have been implicated in a wide range of neurodevelopmental
disorders, including intellectual disability and autism.
explanation: >-
Links ZBTB20 transcriptional repressor defects to intellectual disability
and autism, the core neurodevelopmental features of Primrose syndrome.
- reference: PMID:30281617
reference_title: "Neurodevelopmental disorder-associated ZBTB20 gene variants affect dendritic and synaptic structure."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
a single nucleotide variant identified in patients with intellectual
disability and located at the C-terminus of ZBTB20 affected dendritic
arborization and dendritic length but had no effect on dendritic spine
morphology.
explanation: >-
Demonstrates that ZBTB20 variants perturb dendritic architecture in
cortical pyramidal neurons, a substrate for the cognitive phenotype.
downstream:
- target: Intellectual Disability
causal_link_type: DIRECT
- target: Global Developmental Delay
causal_link_type: DIRECT
- target: Expressive Language Delay
causal_link_type: DIRECT
- target: Autistic Behavior
causal_link_type: DIRECT
- target: Behavioral Abnormality
causal_link_type: DIRECT
- target: Hypotonia
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Frontal Bossing
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Deeply Set Eyes
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Ptosis
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Downslanting Palpebral Fissures
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Sensorineural Hearing Loss
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Seizures
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Corpus Callosum Anomaly
causal_link_type: DIRECT
- name: Disturbed Growth and Energy Metabolism
description: >-
ZBTB20 acts as a regulator of somatic growth, fetal liver development,
detoxification, and glucose metabolism. Its dysregulation in Primrose
syndrome is linked to postnatal overgrowth (macrocephaly, with variable
tall stature), disturbed glucose metabolism with insulin-resistant
diabetes, and a metabolic signature suggesting disturbed mitochondrial
fatty-acid oxidation (abnormal acylcarnitines and urine organic acids).
ZBTB20 normally represses hepatic alpha-fetoprotein expression, and loss of
this repression is proposed to underlie the characteristically elevated
serum AFP.
cell_types:
- preferred_term: Pancreatic beta cell
term:
id: CL:0000169
label: type B pancreatic cell
- preferred_term: Hepatocyte
term:
id: CL:0000182
label: hepatocyte
biological_processes:
- preferred_term: Regulation of glucose metabolic process
term:
id: GO:0010906
label: regulation of glucose metabolic process
modifier: ABNORMAL
- preferred_term: Glucose homeostasis
term:
id: GO:0042593
label: glucose homeostasis
modifier: ABNORMAL
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
ZBTB20 acts as a regulator of neurogenesis, fetal liver development,
somatic growth, detoxification and glucose metabolism.
explanation: >-
Establishes the physiological roles of ZBTB20 in growth and glucose
metabolism whose dysregulation drives the metabolic phenotype.
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Biochemically, unexplained anemia, disturbed glucose metabolism, and
increased AFP levels are cardinal features of PS.
explanation: >-
Documents disturbed glucose metabolism, anemia, and elevated AFP as
cardinal biochemical features arising from ZBTB20 dysfunction.
- reference: PMID:29737001
reference_title: "Clinical and functional characterization of two novel ZBTB20 mutations causing Primrose syndrome."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
The disorder is caused by functional dysregulation of ZBTB20, a
transcriptional repressor controlling energetic metabolism and
developmental programs.
explanation: >-
Frames ZBTB20 dysregulation as the driver of both metabolic and
developmental dysfunction in Primrose syndrome.
downstream:
- target: Macrocephaly
causal_link_type: DIRECT
- target: Tall Stature
causal_link_type: DIRECT
- target: Calcification of the External Ear Cartilage
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Distal Muscle Wasting
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Joint Contractures
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Cataract
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Diabetes Mellitus
causal_link_type: DIRECT
- target: Hypothyroidism
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Cryptorchidism
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Testicular Neoplasm
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
- target: Sparse Body Hair
causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
phenotypes:
- category: Phenotypic abnormality
name: Macrocephaly
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Macrocephaly
term:
id: HP:0000256
label: Macrocephaly
description: >-
Postnatal macrocephaly / macrocrania reflecting non-progressive brain
overgrowth, present in roughly three-quarters of patients.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome (PS; MIM# 259050) is characterized by intellectual
disability (ID), macrocephaly, unusual facial features (frontal bossing,
deeply set eyes, down‐slanting palpebral fissures), calcified external
ears, sparse body hair and distal muscle wasting.
explanation: >-
Lists macrocephaly as a defining feature of Primrose syndrome in the
42-patient cohort.
- category: Phenotypic abnormality
name: Tall Stature
phenotype_term:
preferred_term: Tall stature
term:
id: HP:0000098
label: Tall stature
description: >-
Increased postnatal growth in height; present in a minority of patients and
more marked in males, where growth may exceed the 98th centile.
evidence:
- reference: PMID:25017102
reference_title: "Mutations in ZBTB20 cause Primrose syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome and 3q13.31 microdeletion syndrome are clinically
related disorders characterized by tall stature, macrocephaly,
intellectual disability, disturbed behavior and unusual facial features,
with diabetes, deafness, progressive muscle wasting and ectopic
calcifications specifically occurring in the former.
explanation: >-
The discovery paper lists tall stature among the defining features of
Primrose syndrome.
- category: Phenotypic abnormality
name: Intellectual Disability
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Intellectual disability
term:
id: HP:0001249
label: Intellectual disability
description: >-
Moderate-to-severe intellectual disability in most patients (moderate-severe
in ~84%, mild in ~16%); cognition does not appear to decline with age.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The cardinal findings of PS are the ID (mild 16%, moderate‐severe 84%)
explanation: >-
Quantifies intellectual disability severity in the 42-patient cohort,
supporting both the association and the VERY_FREQUENT band.
- category: Phenotypic abnormality
name: Global Developmental Delay
phenotype_term:
preferred_term: Developmental delay
term:
id: HP:0001263
label: Global developmental delay
description: >-
Developmental delay including expressive speech delay; all 57 patients in a
comparative review had intellectual disability and/or psychomotor delay.
evidence:
- reference: PMID:32071410
reference_title: "Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "All 57 patients presented mild-to-severe ID and/or a psychomotor delay."
explanation: >-
Establishes near-universal developmental delay across the combined
literature cohort.
- category: Phenotypic abnormality
name: Expressive Language Delay
phenotype_term:
preferred_term: Expressive speech delay
term:
id: HP:0002474
label: Expressive language delay
description: >-
Intellectual disability is characteristically accompanied by delayed
expressive speech development.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome is characterized by macrocephaly, hypotonia,
developmental delay, intellectual disability with expressive speech delay,
behavioral issues, a recognizable facial phenotype, radiographic features,
and altered glucose metabolism.
explanation: >-
GeneReviews lists expressive speech delay as a characteristic feature.
- category: Phenotypic abnormality
name: Autistic Behavior
frequency: FREQUENT
phenotype_term:
preferred_term: Autistic behavior
term:
id: HP:0000729
label: Autistic behavior
description: >-
Autism spectrum / autistic behavior reported in roughly 61% of cohort
patients.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
cognitive deficit associated with autism spectrum disorder
explanation: >-
Associates Primrose syndrome cognitive deficit with autism spectrum
disorder.
- category: Phenotypic abnormality
name: Behavioral Abnormality
phenotype_term:
preferred_term: Behavioral abnormality
term:
id: HP:0000708
label: Atypical behavior
description: >-
Behavioral issues are characteristic and can include severe neurobehavioral
dysregulation (aggression, irritability, mood lability) in adolescence.
evidence:
- reference: PMID:38517161
reference_title: "Resolution of severe neurobehavioral difficulties in an individual with Primrose syndrome with sertraline."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Neurobehavioral difficulties included aggression towards self and others,
irritability, tearfulness, and mood liability that did not respond to
behavioral interventions or aripiprazole.
explanation: >-
Documents the severe behavioral phenotype that can occur in Primrose
syndrome.
- category: Phenotypic abnormality
name: Hypotonia
frequency: VERY_FREQUENT
phenotype_term:
preferred_term: Hypotonia
term:
id: HP:0001252
label: Hypotonia
description: >-
Hypotonia, typically of infantile/childhood onset, present in ~76% of cohort
patients and contributing to motor delay.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome is characterized by macrocephaly, hypotonia,
developmental delay, intellectual disability with expressive speech delay,
behavioral issues, a recognizable facial phenotype, radiographic features,
and altered glucose metabolism.
explanation: >-
GeneReviews lists hypotonia as a characteristic feature of Primrose
syndrome.
- category: Phenotypic abnormality
name: Frontal Bossing
phenotype_term:
preferred_term: Frontal bossing
term:
id: HP:0002007
label: Frontal bossing
description: >-
Part of the recognizable craniofacial gestalt, together with deeply set
eyes, ptosis, downslanting palpebral fissures, and large ears.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
unusual facial features (frontal bossing, deeply set eyes, down‐slanting
palpebral fissures)
explanation: >-
Documents frontal bossing as part of the characteristic facial phenotype.
- category: Phenotypic abnormality
name: Deeply Set Eyes
phenotype_term:
preferred_term: Deeply set eyes
term:
id: HP:0000490
label: Deeply set eye
description: >-
Deeply set eyes are a recurring component of the Primrose syndrome facial
gestalt.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
unusual facial features (frontal bossing, deeply set eyes, down‐slanting
palpebral fissures)
explanation: >-
Documents deeply set eyes as part of the facial phenotype.
- category: Phenotypic abnormality
name: Ptosis
frequency: FREQUENT
phenotype_term:
preferred_term: Ptosis
term:
id: HP:0000508
label: Ptosis
description: >-
Ptosis is part of the characteristic facial gestalt, reported in ~71% of
cohort patients.
evidence:
- reference: PMID:39129839
reference_title: "A Novel ZBTB20 Variant in a Patient with Primrose Syndrome: A Rare Clinical Entity with Distinctive Features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a recognizable facial phenotype including deep set eyes, ptosis, narrow
and frequently downslanting palpebral fissures, and depressed nasal
bridge.
explanation: >-
Lists ptosis as part of the recognizable Primrose syndrome facial
phenotype.
- category: Phenotypic abnormality
name: Downslanting Palpebral Fissures
phenotype_term:
preferred_term: Downslanting palpebral fissures
term:
id: HP:0000494
label: Downslanted palpebral fissures
description: >-
Narrow, frequently downslanting palpebral fissures are part of the
craniofacial pattern.
evidence:
- reference: PMID:39129839
reference_title: "A Novel ZBTB20 Variant in a Patient with Primrose Syndrome: A Rare Clinical Entity with Distinctive Features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
a recognizable facial phenotype including deep set eyes, ptosis, narrow
and frequently downslanting palpebral fissures, and depressed nasal
bridge.
explanation: >-
Lists downslanting palpebral fissures as part of the facial phenotype.
- category: Phenotypic abnormality
name: Sensorineural Hearing Loss
frequency: FREQUENT
phenotype_term:
preferred_term: Sensorineural hearing impairment
term:
id: HP:0000407
label: Sensorineural hearing impairment
clinical_course: PROGRESSIVE
description: >-
Hearing loss, mostly sensorineural, is common in both children and adults
and is significantly more frequent in patients with missense variants than
those with deletions/truncating variants.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Hearing loss is also common both in children and adults, mostly presenting
as sensorineural hearing loss.
explanation: >-
Documents common sensorineural hearing loss across age groups.
- reference: PMID:32071410
reference_title: "Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Hearing loss was far more frequent in patients with missense SNVs
(p = 0.002)
explanation: >-
Shows the genotype association of hearing loss with missense variants;
hearing loss was far more frequent in missense-variant patients
(p = 0.002).
- category: Phenotypic abnormality
name: Calcification of the External Ear Cartilage
phenotype_term:
preferred_term: Calcification of the external ear cartilage
term:
id: HP:0100593
label: Calcification of cartilage
clinical_course: PROGRESSIVE
description: >-
Calcification (and ossification) of the external ear cartilage is a cardinal
progressive sign, typically emerging in later childhood/adolescence; present
in essentially all assessed adults. The best-fit HPO term is the broader
"Calcification of cartilage"; the preferred term captures the ear-specific
localization.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Radiographic features include calcification of the external ear cartilage,
multiple wormian bones, platybasia, bathrocephaly, slender bones with
exaggerated metaphyseal flaring, mild epiphyseal dysplasia, and spondylar
dysplasia.
explanation: >-
GeneReviews lists calcification of the external ear cartilage as a
characteristic radiographic feature.
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
the cardinal features, such as calcification of the external ears, cystic
bone lesions, muscle wasting, and contractures typically develop between
10 and 16 years of age.
explanation: >-
Documents external ear calcification as a cardinal, age-dependent
progressive feature.
- category: Phenotypic abnormality
name: Distal Muscle Wasting
phenotype_term:
preferred_term: Distal amyotrophy
term:
id: HP:0003693
label: Distal amyotrophy
clinical_course: PROGRESSIVE
description: >-
Progressive distal muscle wasting, first noticed around age 11 years and
increasing with age; a muscle biopsy in one patient demonstrated neurogenic
atrophy.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Muscle wasting was first noticed at age 11"
explanation: >-
Documents the progressive, age-dependent nature of distal muscle wasting.
- category: Phenotypic abnormality
name: Joint Contractures
phenotype_term:
preferred_term: Joint contractures
term:
id: HP:0001371
label: Flexion contracture
clinical_course: PROGRESSIVE
description: >-
Joint contractures, typically beginning around age 10 years and becoming
more prominent with age, can contribute to mobility disability.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Contractures were first noticed at age 10 years and became more prominent
with age as well.
explanation: >-
Documents progressive joint contractures as an age-related feature.
- category: Phenotypic abnormality
name: Seizures
frequency: OCCASIONAL
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
description: >-
Seizures occur in a subset of patients (~21% in the 42-patient cohort).
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
standard treatment for seizures, musculoskeletal issues, hearing loss, and
thyroid dysfunction
explanation: >-
GeneReviews management addresses seizures as part of the Primrose syndrome
phenotype.
- category: Phenotypic abnormality
name: Corpus Callosum Anomaly
phenotype_term:
preferred_term: Corpus callosum dysgenesis
term:
id: HP:0001273
label: Abnormal corpus callosum morphology
description: >-
Corpus callosum anomalies (dysgenesis/agenesis) are seen on brain MRI,
significantly more frequently in patients with missense variants.
evidence:
- reference: PMID:32071410
reference_title: "Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Corpus callosum dysgenesis"
explanation: >-
Documents corpus callosum dysgenesis enriched among missense-variant
patients.
- reference: PMID:37927765
reference_title: "An Infant With Primrose Syndrome: A Case Report."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
an absent corpus callosum observed on postnatal MRI and genotypic findings
of a pathogenic variant in ZBTB20.
explanation: >-
An infant case report documents absent corpus callosum on MRI.
- category: Phenotypic abnormality
name: Cataract
phenotype_term:
preferred_term: Cataract
term:
id: HP:0000518
label: Cataract
description: >-
Cataract is an age-related feature found in adults with Primrose syndrome.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Dysplastic hip joint changes, cystic bone lesions, and cataract were found only in adults."
explanation: >-
Documents cataract as an adult-onset feature in the cohort.
- category: Phenotypic abnormality
name: Diabetes Mellitus
phenotype_term:
preferred_term: Insulin-resistant diabetes mellitus
term:
id: HP:0000819
label: Diabetes mellitus
description: >-
Disturbed glucose metabolism is a cardinal biochemical feature; adults may
develop insulin-resistant diabetes requiring oral hypoglycemics and/or
insulin.
evidence:
- reference: PMID:29737001
reference_title: "Clinical and functional characterization of two novel ZBTB20 mutations causing Primrose syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
disturbances of glucose metabolism with insulin-resistant diabetes and
distal muscle wasting occurring in adulthood.
explanation: >-
Documents insulin-resistant diabetes as part of the adult metabolic
phenotype.
- category: Phenotypic abnormality
name: Hypothyroidism
phenotype_term:
preferred_term: Hypothyroidism
term:
id: HP:0000821
label: Hypothyroidism
description: >-
Hypothyroidism occurs in a subset of patients and is enriched in the
missense-variant group.
evidence:
- reference: PMID:32071410
reference_title: "Primrose syndrome: a phenotypic comparison of patients with a ZBTB20 missense variant versus a 3q13.31 microdeletion including ZBTB20."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
hypothyroidism (p = 0.047), and diabetes were also more frequent in this
group.
explanation: >-
Documents hypothyroidism (and diabetes) as features enriched among missense-variant
patients.
- category: Phenotypic abnormality
name: Cryptorchidism
phenotype_term:
preferred_term: Cryptorchidism
term:
id: HP:0000028
label: Cryptorchidism
description: >-
Cryptorchidism is reported among affected males.
evidence:
- reference: PMID:39129839
reference_title: "A Novel ZBTB20 Variant in a Patient with Primrose Syndrome: A Rare Clinical Entity with Distinctive Features."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Among other characteristic findings are ocular abnormalities, hearing
loss, calcification of the external ear cartilage, nonspecific brain
magnetic resonance imaging findings, and cryptorchidism.
explanation: >-
Lists cryptorchidism among the characteristic findings of Primrose
syndrome.
- category: Phenotypic abnormality
name: Testicular Neoplasm
phenotype_term:
preferred_term: Testicular neoplasm
term:
id: HP:0010788
label: Testicular neoplasm
description: >-
Adult males with Primrose syndrome are at elevated risk of testicular germ
cell tumors. This is a prognosis-affecting complication: both reported
affected males who developed testicular tumors died of their tumors,
prompting recommendations for surveillance in adult males.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Two adult males with PS developed a testicular tumor."
explanation: >-
Documents testicular tumors as a complication occurring in adult males
with Primrose syndrome.
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The two males with PS who developed testicular tumors have died because of
their tumors.
explanation: >-
Establishes testicular tumors as a mortality-causing complication,
motivating surveillance in adult males.
- category: Phenotypic abnormality
name: Sparse Body Hair
phenotype_term:
preferred_term: Sparse body hair
term:
id: HP:0002231
label: Sparse body hair
description: >-
Sparse body hair is a characteristic feature, most recognizable in adults.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "sparse body hair, distal muscle wasting, and contractures"
explanation: >-
GeneReviews lists sparse body hair among the additional features seen in
adults with Primrose syndrome.
biochemical:
- name: Elevated serum alpha-fetoprotein
biomarker_term:
preferred_term: Elevated circulating alpha-fetoprotein concentration
term:
id: HP:0006254
label: Elevated circulating alpha-fetoprotein concentration
presence: ELEVATED
frequency: FREQUENT
context: >-
Serum AFP is typically elevated (about half of assessed patients) and is a
cardinal biochemical feature. ZBTB20 normally represses hepatic AFP
transcription, so loss of repression is proposed to underlie the elevation.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It has been proposed that mutated ZBTB20 disrupts the AFP repression
resulting in AFP increase and overgrowth.
explanation: >-
Documents elevated AFP and the proposed mechanism of disrupted hepatic AFP
repression by mutant ZBTB20.
- name: Anemia
biomarker_term:
preferred_term: Anemia
term:
id: HP:0001903
label: Anemia
presence: PRESENT
frequency: OCCASIONAL
context: >-
Unexplained anemia is a cardinal biochemical feature, present in ~24% of
cohort patients.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Biochemically, unexplained anemia, disturbed glucose metabolism, and
increased AFP levels are cardinal features of PS.
explanation: >-
Lists unexplained anemia as a cardinal biochemical feature.
- name: Disturbed mitochondrial fatty-acid oxidation signature
presence: ABNORMAL
context: >-
Metabolic investigations in a subset of patients show abnormal acylcarnitine
and urine organic acid profiles (increased dicarboxylic, ethylmalonic and
glutaric acids), suggesting disturbed mitochondrial fatty-acid oxidation.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Metabolic investigations suggest a disturbed mitochondrial fatty acid
oxidation.
explanation: >-
Documents the metabolic fatty-acid-oxidation signature observed in a
subset of patients.
genetic:
- name: ZBTB20 pathogenic variants
gene_term:
preferred_term: ZBTB20
term:
id: hgnc:13503
label: ZBTB20
association: Causative
relationship_type: CAUSATIVE
variant_origin: DE_NOVO
inheritance:
- name: Autosomal dominant
description: >-
Primrose syndrome is an autosomal dominant disorder caused by de novo
heterozygous ZBTB20 variants.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome is an autosomal dominant disorder. All probands
reported to date with Primrose syndrome whose parents have undergone
molecular genetic testing have the disorder as a result of a de novo
ZBTB20 pathogenic variant.
explanation: >-
GeneReviews establishes the autosomal dominant, de novo inheritance of
ZBTB20 variants.
features: >-
Primrose syndrome is caused by de novo heterozygous pathogenic variants in
ZBTB20. The recurrent variants are missense changes affecting the first and
second C2H2 zinc-finger motifs, which disrupt DNA binding; rare truncating
and small-deletion alleles have also been reported. Functional studies
support a dominant-negative mechanism. ZBTB20 lies within the 3q13.31
microdeletion syndrome critical region, explaining clinical overlap between
the two disorders.
evidence:
- reference: PMID:25017102
reference_title: "Mutations in ZBTB20 cause Primrose syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
We report that missense mutations in ZBTB20, residing within the 3q13.31
microdeletion syndrome critical region, underlie Primrose syndrome.
explanation: >-
The discovery paper establishes ZBTB20 missense mutations as the cause of
Primrose syndrome.
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In all patients in whom one or both parents were available (n = 26), the
variant was found to be de novo.
explanation: >-
Confirms the de novo origin of ZBTB20 variants across the cohort.
treatments:
- name: Multidisciplinary Supportive Care
description: >-
No disease-modifying therapy exists; management is multidisciplinary and
symptom-directed, including individualized educational programs and
developmental services, treatment of behavioral concerns, standard treatment
for seizures, musculoskeletal issues, hearing loss, and thyroid dysfunction,
and oral hypoglycemics or insulin for diabetes.
treatment_term:
preferred_term: supportive care
term:
id: MAXO:0000950
label: supportive care
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Individualized educational program, speech therapy, physical therapy, and
occupational therapy as indicated; treatment of behavioral concerns;
applied behavioral analysis for autism; standard treatment for seizures,
musculoskeletal issues, hearing loss, and thyroid dysfunction; oral
hypoglycemics or insulin as needed for diabetes.
explanation: >-
GeneReviews describes the multidisciplinary supportive management of
Primrose syndrome.
- name: Speech Therapy
description: >-
Speech therapy is recommended for expressive speech delay and developmental
impairment.
treatment_term:
preferred_term: speech therapy
term:
id: MAXO:0000930
label: speech therapy
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Individualized educational program, speech therapy, physical therapy, and
occupational therapy as indicated
explanation: >-
GeneReviews recommends speech therapy as part of management.
- name: Physical Therapy
description: >-
Physical therapy supports motor function and musculoskeletal complications.
treatment_term:
preferred_term: Physical Therapy
term:
id: NCIT:C15302
label: Physical Therapy
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Individualized educational program, speech therapy, physical therapy, and
occupational therapy as indicated
explanation: >-
GeneReviews recommends physical therapy as part of management.
- name: Occupational Therapy
description: >-
Occupational therapy supports daily functioning and developmental needs.
treatment_term:
preferred_term: occupational therapy
term:
id: MAXO:0001351
label: occupational therapy
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Individualized educational program, speech therapy, physical therapy, and
occupational therapy as indicated
explanation: >-
GeneReviews recommends occupational therapy as part of management.
- name: Sertraline for Neurobehavioral Difficulties
description: >-
An SSRI (sertraline) led to resolution of severe neurobehavioral
difficulties (aggression, irritability, mood lability) refractory to
behavioral interventions and aripiprazole, with benefit within 2 weeks and
sustained over more than 2 years. Suggests SSRIs may be useful for
neurobehavioral symptoms in Primrose syndrome.
therapeutic_modality: SMALL_MOLECULE
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: sertraline
term:
id: CHEBI:9123
label: sertraline
evidence:
- reference: PMID:38517161
reference_title: "Resolution of severe neurobehavioral difficulties in an individual with Primrose syndrome with sertraline."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Treatment with sertraline, a medication indicated for psychiatric
disorders including anxiety and depression, led to the resolution of
neurobehavioral difficulties after 2 weeks of initiation of medication.
explanation: >-
Documents the clinical response of severe neurobehavioral difficulties to
sertraline.
- name: Cochlear Implantation
description: >-
Cochlear implantation was performed for sensorineural hearing loss in a
child with Primrose syndrome after an unsuccessful hearing-aid trial, with no
intraoperative or postoperative complications, supporting it as a viable
therapeutic approach for Primrose-associated sensorineural hearing loss.
treatment_term:
preferred_term: cochlear device implantation
term:
id: MAXO:0009025
label: cochlear device implantation
evidence:
- reference: PMID:38784957
reference_title: "Cochlear Implantation in Primrose Syndrome with a Novel ZBTB20 Gene Variant."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
This designates cochlear implantation as a viable therapeutic approach for
sensorineural hearing loss linked to Primrose syndrome.
explanation: >-
Documents cochlear implantation as a viable treatment for Primrose-related
sensorineural hearing loss.
- name: Genetic Counseling
description: >-
Genetic counseling with recurrence-risk assessment is recommended. Most
cases are de novo; once the familial ZBTB20 variant is known, prenatal and
preimplantation genetic testing are possible.
treatment_term:
preferred_term: Genetic Counseling
term:
id: NCIT:C15240
label: Genetic Counseling
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Once the ZBTB20 pathogenic variant has been identified in an affected
family member, prenatal testing for a pregnancy at increased risk and
preimplantation genetic testing are possible.
explanation: >-
GeneReviews describes genetic counseling and reproductive testing options.
diagnosis:
- name: Molecular Genetic Diagnosis
description: >-
The diagnosis is established in a proband with characteristic features and a
heterozygous pathogenic variant in ZBTB20 identified on molecular genetic
testing (single-gene testing, multigene ID panels, or exome/genome
sequencing).
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The diagnosis of Primrose syndrome is established in a proband with
characteristic features and a heterozygous pathogenic variant in ZBTB20
identified on molecular genetic testing.
explanation: >-
GeneReviews defines the molecular diagnostic criteria for Primrose
syndrome.
differential_diagnoses:
- name: 3q13.31 Microdeletion Syndrome
description: >-
3q13.31 microdeletion syndrome encompasses ZBTB20 and shares features such as
macrocephaly, intellectual disability, disturbed behavior, and unusual
facial features, but the progressive components (diabetes, deafness, muscle
wasting, ectopic calcifications) occur specifically in Primrose syndrome.
evidence:
- reference: PMID:25017102
reference_title: "Mutations in ZBTB20 cause Primrose syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome and 3q13.31 microdeletion syndrome are clinically
related disorders characterized by tall stature, macrocephaly,
intellectual disability, disturbed behavior and unusual facial features,
with diabetes, deafness, progressive muscle wasting and ectopic
calcifications specifically occurring in the former.
explanation: >-
Establishes the clinical relationship and distinguishing features between
Primrose syndrome and 3q13.31 microdeletion syndrome.
progression:
- phase: Early childhood neurodevelopmental presentation
age_range: Infancy through childhood
notes: >-
Primrose syndrome presents in infancy and childhood with macrocephaly,
hypotonia, developmental delay, and intellectual disability with expressive
speech delay, together with behavioral issues and a recognizable facial
phenotype. The condition is difficult to recognize in infants and young
children.
evidence:
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Primrose syndrome is characterized by macrocephaly, hypotonia,
developmental delay, intellectual disability with expressive speech delay,
behavioral issues, a recognizable facial phenotype, radiographic features,
and altered glucose metabolism.
explanation: >-
GeneReviews summarizes the core neurodevelopmental presentation that
dominates the early childhood phase.
- phase: Adolescent emergence of progressive somatic features
age_range: 10 to 16 years
notes: >-
A hallmark progressive somatic component emerges in adolescence, typically
between 10 and 16 years of age, including calcification of the external ear
cartilage, cystic bone lesions, distal muscle wasting, and joint
contractures.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
lesions, muscle wasting, and contractures typically develop between 10 and
16 years of age.
explanation: >-
Documents the characteristic adolescent onset of progressive somatic
features.
- phase: Adult progressive course
age_range: Adulthood
notes: >-
Primrose syndrome is a progressive entity in adults, with sparse body hair,
distal muscle wasting, and contractures becoming recognizable; disturbed
glucose metabolism with insulin-resistant diabetes and an elevated risk of
testicular germ cell tumors in males are prognosis-affecting features.
Cognition does not appear to decline with age.
evidence:
- reference: PMID:32266967
reference_title: "Primrose syndrome: Characterization of the phenotype in 42 patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Although PS should be regarded as a progressive entity, there are no
indications that cognition becomes more impaired with age.
explanation: >-
Establishes the progressive nature of the disorder while noting cognition
is generally stable over time.
- reference: PMID:33956417
reference_title: "Primrose Syndrome."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Additional features seen in adults: sparse body hair, distal muscle
wasting, and contractures.
explanation: >-
GeneReviews lists the somatic features that become prominent in adults.
animal_models:
- species: Rat
description: >-
Rodent ZBTB20 perturbation models inform Primrose syndrome neurodevelopmental
mechanisms: ZBTB20 regulates hippocampal development and cortical lamination,
and neurodevelopmental-disorder-associated variants alter dendritic spine
morphology and dendritic arborization in cultured cortical pyramidal neurons.
genes:
- preferred_term: ZBTB20
term:
id: hgnc:13503
label: ZBTB20
evidence:
- reference: PMID:30281617
reference_title: "Neurodevelopmental disorder-associated ZBTB20 gene variants affect dendritic and synaptic structure."
supports: SUPPORT
evidence_source: IN_VITRO
snippet: >-
Here we show distinct effects of expression of two major isoforms, long
and short, of ZBTB20, and its neurodevelopmental disorder-linked variants,
on dendritic architecture of cultured rat cortical pyramidal neurons.
explanation: >-
Rat cortical neuron experiments demonstrate the effect of ZBTB20 variants
on dendritic architecture.
datasets: []
Primrose syndrome is a rare, typically de novo autosomal dominant multisystem disorder characterized by neurodevelopmental impairment (developmental delay, intellectual disability, behavioral abnormalities including autism), postnatal macrocephaly, characteristic facial features, and a progressive component with calcification/ossification of the external ears, distal muscle wasting, contractures, skeletal abnormalities, and metabolic/endocrine disturbances (including altered glucose metabolism/diabetes and thyroid dysfunction). (melis2020primrosesyndromecharacterization pages 2-4, arora2021primrosesyndrome pages 1-3, melis2020primrosesyndromecharacterization pages 1-2)
A commonly used resource synonym is “Intellectual disability - cataracts - calcified pinnae - myopathy” (Orphanet_3042), reflecting the characteristic clinical tetrad in some individuals. (OpenTargets Search: Primrose syndrome-ZBTB20)
Most knowledge is derived from aggregated disease-level resources and cohorts (notably a 42-patient series), plus individual case reports—including multiple 2023–2024 publications that expand early-life phenotypes and management experience. (melis2020primrosesyndromecharacterization pages 2-4, li2024noveldenovo pages 1-2, tugci2024cochlearimplantationin pages 2-4)
Primrose syndrome is caused by heterozygous pathogenic (or likely pathogenic) variants in ZBTB20, encoding a BTB–zinc finger transcriptional repressor. (arora2021primrosesyndrome pages 10-13, sogukpınar2024anovelzbtb20 pages 1-2)
No protective factors or gene–environment interactions specific to Primrose syndrome were identified in the retrieved evidence.
The largest consolidated cohort evidence in the retrieved texts is the 42-patient phenotype series, which provides frequencies for multiple core findings. Examples include: - Macrocephaly: 29/38 (76%) (melis2020primrosesyndromecharacterization pages 2-4) - Moderate–severe intellectual disability: 33/39 (85%) (melis2020primrosesyndromecharacterization pages 2-4) - Autism: 20/33 (61%) (melis2020primrosesyndromecharacterization pages 2-4) - Hypotonia: 26/34 (76%) (melis2020primrosesyndromecharacterization pages 2-4) - External ear calcification: 14/28 (50%) overall, but 12/12 adults (100%) where assessed (melis2020primrosesyndromecharacterization pages 2-4)
Phenotypes with strong age-dependence (often emerging in adolescence) include ear calcification, cystic bone lesions, muscle wasting, and contractures. (melis2020primrosesyndromecharacterization pages 1-2)
A consistent theme across cohort and review sources is progressive somatic involvement: - Cardinal features such as calcification of the external ears, cystic bone lesions, muscle wasting, and contractures “typically develop between 10 and 16 years of age.” (melis2020primrosesyndromecharacterization pages 1-2) - Muscle wasting may first be noticed around 11 years, and contractures around 10 years, with progression over time. (melis2020primrosesyndromecharacterization pages 4-7)
Functional impairment can become substantial due to musculoskeletal progression; GeneReviews-style content notes walking difficulty and eventual wheelchair dependence in some individuals due to distal wasting and contractures. (arora2021primrosesyndromea pages 6-8)
A phenotype-to-HPO mapping (including onset and frequency where available) is provided in Artifact 01.
| Phenotype | Suggested HPO term(s) | Onset/course | Frequency/evidence |
|---|---|---|---|
| Macrocephaly / macrocrania | HP:0000256 Macrocephaly | Usually postnatal overgrowth; non-progressive overgrowth pattern recognized from infancy/childhood | 29/38 (76%) in 42-patient cohort; GeneReviews notes postnatal macrocephaly common (melis2020primrosesyndromecharacterization pages 2-4, melis2020primrosesyndromecharacterization pages 8-10, arora2021primrosesyndrome pages 1-3) |
| Intellectual disability | HP:0001249 Intellectual disability | Developmental onset; cognition appears relatively stable, with no clear evidence of decline over time | Moderate-severe ID in 33/39 (85%); mild 16%, moderate-severe 84% in cohort summaries (melis2020primrosesyndromecharacterization pages 2-4, melis2020primrosesyndromecharacterization pages 8-10, melis2020primrosesyndromecharacterization pages 1-2) |
| Developmental delay / psychomotor delay | HP:0001263 Global developmental delay; HP:0011344 Severe global developmental delay (if severe) | Early childhood onset; persistent | All 57 patients in comparative review had ID and/or psychomotor delay; GeneReviews highlights early developmental delay and expressive speech delay (juven2020primrosesyndromea pages 1-2, arora2021primrosesyndrome pages 1-3) |
| Expressive speech delay | HP:0002474 Expressive language delay | Early childhood; major developmental concern requiring early therapy | Frequent, but no firm cohort percentage in extracted text; specifically emphasized in GeneReviews-style management summary (arora2021primrosesyndrome pages 1-3, arora2021primrosesyndrome pages 6-8) |
| Autism spectrum / autistic behavior | HP:0000729 Autism | Childhood onset; behavioral severity variable | Autism in 20/33 (61%) in cohort (melis2020primrosesyndromecharacterization pages 2-4) |
| Hypotonia | HP:0001252 Hypotonia | Typically infancy/childhood; may contribute to motor delay | 26/34 (76%) in cohort (melis2020primrosesyndromecharacterization pages 2-4) |
| Ptosis | HP:0000508 Ptosis | Congenital/childhood, part of characteristic facial gestalt | 20/28 (71%) in cohort (melis2020primrosesyndromecharacterization pages 2-4) |
| Deep-set eyes / characteristic facies | HP:0000490 Deeply set eye; HP:0001999 Facial asymmetry not specifically supported; HP:0000007 Autosomal dominant inheritance not phenotype | Present from childhood; recognizable facial pattern becomes more evident with age | Frequent descriptive feature in recent case reports and GeneReviews summary; no exact percentage in extracted cohort text (sogukpınar2024anovelzbtb20 pages 1-2, arora2021primrosesyndrome pages 1-3) |
| Downslanting palpebral fissures | HP:0000494 Downslanted palpebral fissures | Childhood; part of craniofacial pattern | Common descriptive feature; no exact percentage in extracted text (sogukpınar2024anovelzbtb20 pages 1-2, arora2021primrosesyndrome pages 1-3) |
| Sensorineural hearing loss | HP:0000407 Sensorineural hearing impairment | Often prelingual; may become more evident over time; enriched in missense-variant cases | Hearing loss common: 21/27 children and 12/13 adults in GeneReviews summary; significantly more frequent with missense variants vs deletions/truncating variants (arora2021primrosesyndromea pages 6-8, juven2020primrosesyndromea pages 1-2, tugci2024cochlearimplantationin pages 2-4) |
| Calcification/ossification of external ears | HP:0008608 Calcification of pinna; HP:0011397 Abnormal external ear cartilage (broader fallback) | Typically develops in later childhood/adolescence; one of the hallmark progressive signs | 14/28 (50%) overall and 12/12 (100%) adults in cohort; cardinal features usually emerge between 10-16 years (melis2020primrosesyndromecharacterization pages 2-4, melis2020primrosesyndromecharacterization pages 1-2) |
| Distal muscle wasting / distal amyotrophy | HP:0003699 Amyotrophy; HP:0008947 Distal amyotrophy | Usually first noticed around age 11; progressive with age | Progressive; clear age-related increase in cohort, first noticed around age 11 (melis2020primrosesyndromecharacterization pages 4-7) |
| Joint contractures | HP:0001371 Flexion contracture; HP:0002829 Arthrogryposis multiplex congenita not supported | Typically begins around age 10; progressive | Appears in later childhood/adolescence; worsens with age (melis2020primrosesyndromecharacterization pages 4-7) |
| Ataxia / gait difficulty | HP:0001251 Ataxia; HP:0001288 Gait disturbance | Rare; may be progressive in some individuals | Reported in subset only; GeneReviews notes progressive musculoskeletal impairment can lead to walking difficulty and eventual wheelchair dependence (arora2021primrosesyndrome pages 6-8, arora2021primrosesyndromea pages 6-8) |
| Seizures | HP:0001250 Seizure | Variable onset; monitor clinically for new seizures | 6/29 (21%) in cohort (melis2020primrosesyndromecharacterization pages 2-4) |
| Corpus callosum anomaly / dysgenesis | HP:0001273 Agenesis of corpus callosum; HP:0006989 Dysgenesis of corpus callosum | Congenital/early neuroimaging finding | More frequent in missense SNV group; ~20% reported in recent review/case synthesis (juven2020primrosesyndromea pages 1-2, li2024noveldenovo pages 5-7, long2023aninfantwith pages 1-2) |
| Cataract | HP:0000518 Cataract | Often later-onset; may become apparent in puberty/adulthood | Adult-enriched feature; included among age-related manifestations in cohort and reviews (melis2020primrosesyndromecharacterization pages 1-2, melis2020primrosesyndromecharacterization pages 8-10, arora2021primrosesyndromea pages 6-8) |
| Disturbed glucose metabolism / diabetes mellitus | HP:0003074 Hyperglycemia; HP:0000819 Diabetes mellitus | Usually later childhood/adulthood; progressive metabolic monitoring recommended | Considered a cardinal biochemical feature; adults may require oral hypoglycemics and/or insulin (melis2020primrosesyndromecharacterization pages 8-10, arora2021primrosesyndromea pages 6-8, arora2021primrosesyndromea pages 10-13) |
| Elevated alpha-fetoprotein | HP:0005914 Increased circulating alpha-fetoprotein level | Can be elevated from infancy and may persist without clear age-related trend in some individuals | 9/18 (50%) overall in cohort; 4/11 and 5/7 in subgroups (melis2020primrosesyndromecharacterization pages 4-7) |
| Anemia | HP:0001903 Anemia | Variable; part of biochemical phenotype, may warrant repeated monitoring | 5/21 (24%) overall in cohort (melis2020primrosesyndromecharacterization pages 4-7, melis2020primrosesyndromecharacterization pages 1-2) |
| Sparse body hair | HP:0008070 Sparse body hair | More recognizable with age/adulthood | Described as characteristic adult feature; no exact percentage in extracted text (melis2020primrosesyndromecharacterization pages 1-2, arora2021primrosesyndromea pages 6-8) |
| Cryptorchidism | HP:0000028 Cryptorchidism | Congenital/childhood in affected males | About half of affected males in GeneReviews summary (sogukpınar2024anovelzbtb20 pages 1-2, arora2021primrosesyndromea pages 6-8) |
| Hypothyroidism | HP:0000821 Hypothyroidism | Congenital or childhood-onset in subset; endocrine surveillance recommended | Rare overall but enriched in missense-variant group in comparative study; several cases reported in recent review (juven2020primrosesyndromea pages 1-2, li2024noveldenovo pages 1-2, arora2021primrosesyndromea pages 6-8) |
| Behavioral dysregulation / aggression / self-injury | HP:0000708 Behavioral abnormality; HP:0000734 Stereotypy; HP:0000742 Self-injurious behavior | Childhood to adolescence; variable severity | Common behavioral phenotype in GeneReviews; severe case showed response to sertraline in 2024 report (arora2021primrosesyndrome pages 1-3, moon2024resolutionofsevere pages 1-2) |
Table: This table maps major Primrose syndrome manifestations to suggested HPO terms with onset/progression notes and frequency data where available, mainly from the 42-patient cohort and GeneReviews-style summary. It is useful for disease knowledge base curation and phenotype annotation.
Across case reports and cohort summaries, most disease-causing ZBTB20 variants are reported as de novo and frequently missense variants in C-terminal C2H2 zinc-finger motifs, consistent with disruption of DNA binding and/or dominant-negative behavior. (sogukpınar2024anovelzbtb20 pages 1-2, juven2020primrosesyndromea pages 1-2)
Recent variant examples (2023–2024): - c.1916G>A (p.Cys639Tyr) (de novo) in a 2024 behavioral-treatment case. (moon2024resolutionofsevere pages 1-2) - c.1948A>C (p.Asn650His) (de novo) in an early-childhood presentation. (sogukpınar2024anovelzbtb20 pages 1-2) - c.1927T>A (p.Phe643Ile) (de novo), classified ACMG “likely pathogenic” with PS2 + PM2_supporting + PP3 + PP4. (li2024noveldenovo pages 5-7) - A reported frameshift/truncating variant c.1038dup (p.Ile347AspfsTer23) identified by fetal exome sequencing in a prenatal diagnosis report, illustrating that non-missense loss-of-function alleles can also occur in published cases (though classic Primrose syndrome is enriched for missense ZnF variants). (long2023aninfantwith pages 1-2)
Multiple sources suggest that a dominant-negative mechanism is plausible/likely for many missense zinc-finger variants: - A GeneReviews-style summary explicitly states: “A dominant-negative mechanism has been proposed.” (arora2021primrosesyndrome pages 10-13) - Functional work showed mutant ZBTB20 proteins localize to the nucleus but are not stably chromatin bound and reduce DNA binding even when co-expressed with wild-type, supporting interference with normal function. (stellacci2018clinicalandfunctional pages 13-16) - Genotype–phenotype comparisons report that missense SNVs are associated with more progressive multisystem involvement (hearing loss, ectopic calcifications, muscle wasting/contractures) than 3q13.31 deletions/truncating variants, consistent with stronger dominant-negative effects for some missense alleles. (juven2020primrosesyndromea pages 1-2)
No disease-specific environmental, lifestyle, or infectious triggers were identified in the retrieved evidence; Primrose syndrome is primarily genetic in etiology. (arora2021primrosesyndrome pages 10-13, sogukpınar2024anovelzbtb20 pages 1-2)
ZBTB20 is a BTB-ZF transcriptional repressor with an N-terminal BTB domain (protein–protein interactions) and C-terminal C2H2 zinc fingers (DNA binding). (arora2021primrosesyndrome pages 10-13, arora2021primrosesyndromea pages 10-13)
A proposed mechanism for a characteristic biomarker is that ZBTB20 normally represses AFP expression in liver; ZBTB20 dysfunction “leads to the unblocking of AFP synthesis in the liver (normally, the gene acts as a repressor)” leading to elevated serum AFP in Primrose syndrome. (głowskaciemny2023roleofalphafetoprotein pages 3-4, głowskaciemny2023roleofalphafetoprotein pages 4-6)
Neurodevelopmental disorder mechanisms are supported by animal and cellular neurobiology work: - ZBTB20 perturbation affects hippocampal development and CA1 pyramidal neuron maturation; RNAi downregulation in mouse hippocampus reduces apical dendritic arborization, and genetic models show hippocampal circuit defects. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2) - Cultured neuron experiments show ZBTB20 variants can alter dendritic spine morphology and dendritic arborization/length, providing a plausible substrate for cognition/behavior phenotypes. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2)
Clinical biochemical patterns and mechanistic studies link ZBTB20 to metabolic homeostasis: - Clinically, “unexplained anemia, disturbed glucose metabolism, and increased AFP levels are cardinal features of PS,” and metabolic investigations suggest disturbed mitochondrial fatty-acid oxidation with abnormal acylcarnitines and urine organic acids in a subset. (melis2020primrosesyndromecharacterization pages 8-10, melis2020primrosesyndromecharacterization pages 4-7) - Functional and review evidence links ZBTB20 to regulation of metabolic genes and β-cell function relevant to glucose homeostasis. (stellacci2018clinicalandfunctional pages 13-16)
Functional assays in a Primrose-syndrome–relevant context found that ZnF-region substitutions can disrupt DNA contacts (loss of a DNA-backbone hydrogen bond) and reduce chromatin binding/DNA binding to an AFP promoter oligo, consistent with a transcriptional dysregulation mechanism and dominant-negative interference with wild-type protein. (stellacci2018clinicalandfunctional pages 13-16)
(These ontology suggestions are aligned with functional roles reported in mechanistic evidence but are not explicitly enumerated in the retrieved excerpts.) (stellacci2018clinicalandfunctional pages 13-16, jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2)
Primrose syndrome is autosomal dominant, and most reported probands are de novo. (arora2021primrosesyndrome pages 10-13, long2023aninfantwith pages 1-2)
If the pathogenic variant is present in an affected parent, recurrence risk to sibs is 50%; if parental leukocyte testing is negative, sib recurrence risk is estimated ~1% due to possible germline mosaicism. (arora2021primrosesyndrome pages 10-13, arora2021primrosesyndromea pages 10-13)
Robust incidence/prevalence data are not available from the extracted primary cohort excerpts; one review-style AFP paper cites a rough prevalence of ~1:1,000,000 births. (głowskaciemny2023roleofalphafetoprotein pages 3-4)
Clinical suspicion is raised by the combination of neurodevelopmental impairment, macrocephaly/overgrowth, hearing loss, progressive ear calcification and muscle wasting/contractures, and supportive biochemical features (AFP elevation, anemia, glucose dysregulation, occasional metabolic profiling abnormalities). (melis2020primrosesyndromecharacterization pages 2-4, melis2020primrosesyndromecharacterization pages 8-10)
A GeneReviews-style diagnostic workflow includes: - Single-gene testing of ZBTB20 (sequence analysis), followed by deletion/duplication analysis if negative. - Alternatively, multigene panels for intellectual disability that include ZBTB20, or exome/genome sequencing when the phenotype is nonspecific. - ACMG/AMP interpretation: pathogenic/likely pathogenic variants are diagnostic; VUS does not establish/exclude diagnosis. (arora2021primrosesyndrome pages 1-3)
Recent real-world implementations include trio whole-exome sequencing with Sanger confirmation and CNV testing (CNV-seq). (li2024noveldenovo pages 5-7)
Differentials explicitly mentioned include 3q13.31 microdeletion syndrome (including ZBTB20), Fragile X syndrome, and DiGeorge syndrome, reflecting overlapping neurodevelopmental phenotypes. (long2023aninfantwith pages 6-7)
Primrose syndrome is progressive for many somatic features (muscle wasting, contractures, calcifications), but available cohort evidence suggests no clear progressive cognitive decline: cognition “does not seem to decline with age,” though detailed longitudinal testing is limited. (melis2020primrosesyndromecharacterization pages 8-10)
Longitudinal outcome data are limited; the oldest reported individual is 53 years in GeneReviews-style and case report summaries. (arora2021primrosesyndromea pages 6-8, long2023aninfantwith pages 6-7)
A 2024 case report indicates substantial sustained improvement in severe neurobehavioral symptoms with sertraline (resolution within 2 weeks; persisted >2 years), enabling better participation in therapy and schooling (functional benefit). (moon2024resolutionofsevere pages 2-2)
No disorder-specific disease-modifying treatment is established; management is multidisciplinary supportive care, including early intervention (speech/OT/PT), educational planning, behavioral assessment, seizure monitoring and standard ASM use when indicated, orthopedics/rehabilitation for musculoskeletal complications, audiology monitoring and hearing aids, and endocrine surveillance/management (glucose/HbA1c beginning ~age 7; thyroid monitoring). (arora2021primrosesyndrome pages 8-10, arora2021primrosesyndromea pages 10-13)
(These MAXO suggestions are based on interventions described in the clinical evidence and are provided for knowledge base mapping.) (arora2021primrosesyndrome pages 8-10, tugci2024cochlearimplantationin pages 2-4, moon2024resolutionofsevere pages 2-2)
A clinical trials search returned no clearly Primrose syndrome/ZBTB20-targeted interventional trials in the retrieved set; listed trials were unrelated false positives (e.g., “primrose oil”).
Primrose syndrome is genetic; therefore prevention is primarily reproductive/genetic: - Genetic counseling with recurrence risk assessment. - Prenatal and preimplantation genetic testing are possible once the familial ZBTB20 pathogenic variant is known. (arora2021primrosesyndrome pages 10-13, arora2021primrosesyndromea pages 10-13)
Secondary/tertiary prevention focuses on anticipatory surveillance: audiology, glucose/HbA1c, thyroid function, musculoskeletal monitoring, and in adult males consideration of testicular tumor vigilance (though no standardized TGCT surveillance protocol exists). (arora2021primrosesyndromea pages 10-13, melis2020primrosesyndromecharacterization pages 8-10)
No naturally occurring veterinary/other-species disease equivalent was identified in the retrieved evidence; however, multiple mouse experimental models of Zbtb20 perturbation exist that inform neurodevelopmental mechanisms. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2)
Experimental evidence relevant to Primrose syndrome mechanisms includes: - Mouse genetic perturbation / transgenic expression: Zbtb20 deletion or ectopic expression affects hippocampal development and cortical lamination; CA1 pyramidal neuron maturation is sensitive to Zbtb20 downregulation. (jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2) - In vitro/cell-based functional assays: mutant ZBTB20 proteins show impaired chromatin/DNA binding and interference with wild-type binding, supporting dominant-negative effects. (stellacci2018clinicalandfunctional pages 13-16)
The most clinically actionable 2023–2024 developments in the retrieved literature are: 1. Medication response report: sertraline leading to sustained resolution of severe neurobehavioral symptoms (2024). (moon2024resolutionofsevere pages 2-2) 2. Device-based intervention: first reported cochlear implantation experience in Primrose syndrome with short-term audiologic/language gains (2024). (tugci2024cochlearimplantationin pages 2-4) 3. Expanded early-life recognition and prenatal diagnosis: fetal exome sequencing with prenatal imaging features and novel truncating variant (2023), and additional infant/toddler cases with early features before classic adolescence-onset signs (2024). (long2023aninfantwith pages 1-2, sogukpınar2024anovelzbtb20 pages 1-2) 4. Variant spectrum and ACMG-coded interpretation: first Chinese case with de novo p.F643I, classified likely pathogenic with explicit ACMG evidence codes (2024). (li2024noveldenovo pages 5-7)
| Category | Item | Details/statistics | Key sources (author-year) | URL/DOI if available |
|---|---|---|---|---|
| Identifiers / synonyms | Primrose syndrome | Rare autosomal dominant multisystem neurodevelopmental syndrome caused by ZBTB20 variants; major identifiers include OMIM 259050 and MONDO: MONDO_0009798 (arora2021primrosesyndrome pages 10-13, OpenTargets Search: Primrose syndrome-ZBTB20) | Arora 2021; OpenTargets | OMIM: https://omim.org/entry/259050 |
| Identifiers / synonyms | Causal gene | ZBTB20 (OMIM 606025), BTB-zinc finger transcriptional repressor; disease-target association supported in curated disease resources (arora2021primrosesyndrome pages 10-13, OpenTargets Search: Primrose syndrome-ZBTB20) | Arora 2021; OpenTargets | OMIM: https://omim.org/entry/606025 |
| Identifiers / synonyms | Synonym / Orphanet-linked label | Orphanet-linked disease name: Intellectual disability - cataracts - calcified pinnae - myopathy; OpenTargets maps this to Orphanet_3042 and Primrose syndrome to MONDO_0009798 (OpenTargets Search: Primrose syndrome-ZBTB20) | OpenTargets | https://platform.opentargets.org |
| Epidemiology | Reported rarity | Review source cites prevalence around ~1:1,000,000 births; evidence base remains sparse and largely case-report/cohort-based (głowskaciemny2023roleofalphafetoprotein pages 3-4) | Głowska-Ciemny 2023 | https://doi.org/10.3390/cancers15174302 |
| Core phenotype | Macrocephaly / head circumference >2 SD | 29/38 (76%) in 42-patient cohort; often postnatal overgrowth pattern (melis2020primrosesyndromecharacterization pages 2-4) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Core phenotype | Intellectual disability | Moderate-severe ID in 33/39 (85%); overall literature review also notes all 57 compared patients had ID and/or psychomotor delay (melis2020primrosesyndromecharacterization pages 2-4, juven2020primrosesyndromea pages 1-2) | Melis 2020; Juven 2020 | https://doi.org/10.1111/cge.13749 ; https://doi.org/10.1038/s41431-020-0582-3 |
| Core phenotype | Autism / behavioral abnormalities | Autism reported in 20/33 (61%); severe neurobehavioral dysregulation can occur in adolescence (melis2020primrosesyndromecharacterization pages 2-4, moon2024resolutionofsevere pages 1-2) | Melis 2020; Moon 2024 | https://doi.org/10.1111/cge.13749 ; https://doi.org/10.1002/ajmg.a.63610 |
| Core phenotype | Hypotonia | 26/34 (76%) in cohort, typically early-life/childhood manifestation (melis2020primrosesyndromecharacterization pages 2-4) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Core phenotype | Ptosis / facial gestalt | Ptosis in 20/28 (71%); characteristic face includes deep-set eyes, ptosis, narrow/downslanting palpebral fissures, depressed nasal bridge (melis2020primrosesyndromecharacterization pages 2-4, sogukpınar2024anovelzbtb20 pages 1-2) | Melis 2020; Soğukpınar 2024 | https://doi.org/10.1111/cge.13749 ; https://doi.org/10.1159/000537952 |
| Core phenotype | Hearing loss | Common and often prelingual; GeneReviews-style summary: 21/27 children and 12/13 adults affected; missense cases more frequently affected than deletion/truncating groups (arora2021primrosesyndromea pages 6-8, juven2020primrosesyndromea pages 1-2) | Arora 2021; Juven 2020 | GeneReviews chapter; https://doi.org/10.1038/s41431-020-0582-3 |
| Core phenotype | External ear calcification | 14/28 (50%) overall, but 12/12 (100%) adults in cohort where assessed; highly age-dependent (melis2020primrosesyndromecharacterization pages 2-4) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Core phenotype | Seizures | 6/29 (21%) in cohort (melis2020primrosesyndromecharacterization pages 2-4) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Age of onset / progression | Cardinal progressive features | Calcified ears, cystic bone lesions, muscle wasting, and contractures typically emerge between 10 and 16 years; syndrome is progressive somatically but cognition does not clearly worsen (melis2020primrosesyndromecharacterization pages 1-2) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Age of onset / progression | Muscle wasting / contractures | Muscle wasting first noted around 11 years and contractures around 10 years, both increasing with age (melis2020primrosesyndromecharacterization pages 4-7) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Biochemical markers | Elevated alpha-fetoprotein (AFP) | Elevated in 9/18 (50%) overall; subgroup breakdown 4/11 (36%) and 5/7 (71%); reported as often persistent over time (melis2020primrosesyndromecharacterization pages 4-7) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Biochemical markers | AFP mechanism | Proposed mechanism: ZBTB20 normally represses hepatic AFP transcription; loss/dysfunction may “unblock” AFP synthesis (głowskaciemny2023roleofalphafetoprotein pages 3-4) | Głowska-Ciemny 2023 | https://doi.org/10.3390/cancers15174302 |
| Biochemical markers | Anemia | 5/21 (24%) overall; subgroup counts 4/16 (25%) and 1/5 (20%) (melis2020primrosesyndromecharacterization pages 4-7) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Biochemical markers | Glucose dysregulation | Disturbed glucose metabolism is a cardinal biochemical feature; adults may develop diabetes requiring oral agents and/or insulin (melis2020primrosesyndromecharacterization pages 8-10, arora2021primrosesyndromea pages 6-8) | Melis 2020; Arora 2021 | https://doi.org/10.1111/cge.13749 ; GeneReviews chapter |
| Biochemical markers | Metabolic profiling / FAO signature | Abnormal acylcarnitines and urine organic acids reported in some patients, suggesting disturbed mitochondrial fatty-acid oxidation (melis2020primrosesyndromecharacterization pages 4-7, melis2020primrosesyndromecharacterization pages 1-2) | Melis 2020 | https://doi.org/10.1111/cge.13749 |
| Recent case report (2023) | Prenatal diagnosis with novel truncating variant | Fetal US/MRI showed corpus callosum agenesis/colpocephaly; fetal exome identified heterozygous c.1038dup (p.Ile347AspfsTer23), de novo/likely pathogenic; highlights prenatal genomic diagnosis (long2023aninfantwith pages 1-2) | Long 2023 | https://doi.org/10.7759/cureus.46546 |
| Recent case report (2024) | Sertraline for severe neurobehavioral symptoms | 17-year-old with de novo c.1916G>A (p.C639Y) had aggression, irritability, mood lability refractory to guanfacine/aripiprazole; sertraline 25 mg/day led to marked resolution within 2 weeks, later increased to 50 mg/day, with benefit persisting >2 years (moon2024resolutionofsevere pages 2-2, moon2024resolutionofsevere pages 1-2) | Moon 2024 | https://doi.org/10.1002/ajmg.a.63610 |
| Recent case report (2024) | Cochlear implantation | Child with Primrose syndrome and bilateral sensorineural hearing loss underwent unilateral Nucleus CI422 implantation at age 2 after failed 6-month hearing-aid trial; at 3 months post-op free-field PTA 40 dB, basic 1–3 word sentences, near-continuous device use (tugci2024cochlearimplantationin pages 2-4) | Tuğci 2024 | https://doi.org/10.4274/tao.2023.2023-4-5 |
| Recent case report (2024) | Novel infant presentation | 14-month-old girl with de novo c.1948A>C (p.Asn650His); hearing loss and neurodevelopmental findings present before classic later-onset features such as ear calcification or muscle atrophy (sogukpınar2024anovelzbtb20 pages 1-2) | Soğukpınar 2024 | https://doi.org/10.1159/000537952 |
| Recent case report (2024) | First Chinese case / ACMG-classified variant | 5-year-old boy with agenesis of corpus callosum, macrocephaly, motor/speech delay, mild ID, autistic behavior; trio WES found de novo c.1927T>A (p.F643I) in Zn-finger domain, ACMG likely pathogenic (PS2+PM2_supporting+PP3+PP4) (li2024noveldenovo pages 1-2, li2024noveldenovo pages 5-7) | Li 2024 | https://doi.org/10.1002/mgg3.2304 |
| Management / surveillance | Standard care model | Multidisciplinary supportive care: speech/OT/PT, developmental services, annual audiology, annual fasting/postprandial glucose and HbA1c (starting ~age 7 or earlier if indicated), thyroid assessment, seizure and musculoskeletal monitoring; no disorder-specific guidelines yet (arora2021primrosesyndrome pages 8-10, arora2021primrosesyndromea pages 10-13) | Arora 2021 | GeneReviews chapter |
Table: This table condenses high-yield identifiers, phenotype frequencies, biochemical markers, and recent 2023-2024 case reports for Primrose syndrome. It is designed as a quick-reference artifact for knowledge base curation and evidence-backed clinical summary writing.
References
(OpenTargets Search: Primrose syndrome-ZBTB20): Open Targets Query (Primrose syndrome-ZBTB20, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.
(melis2020primrosesyndromecharacterization pages 2-4): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.
(arora2021primrosesyndrome pages 1-3): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.
(melis2020primrosesyndromecharacterization pages 1-2): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.
(arora2021primrosesyndrome pages 10-13): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.
(sogukpınar2024anovelzbtb20 pages 1-2): Merve Soğukpınar, Beren Karaosmanoğlu, Gülen Eda Utine, Koray Boduroğlu, and Pelin Özlem Şimşek-Kiper. A novel zbtb20 variant in a patient with primrose syndrome: a rare clinical entity with distinctive features. Molecular Syndromology, 15:347-354, Mar 2024. URL: https://doi.org/10.1159/000537952, doi:10.1159/000537952. This article has 0 citations and is from a peer-reviewed journal.
(li2024noveldenovo pages 1-2): Jiayi Li, Chuan Zhang, Xinyuan Tian, Bingbo Zhou, Xue Chen, Yupei Wang, Shengju Hao, Ling Hui, and Zhaoyan Meng. Novel de novo mutation in zbtb20 in a chinese primrose syndrome family and a review of the literature. Molecular Genetics & Genomic Medicine, Dec 2024. URL: https://doi.org/10.1002/mgg3.2304, doi:10.1002/mgg3.2304. This article has 1 citations and is from a peer-reviewed journal.
(tugci2024cochlearimplantationin pages 2-4): Burak Anıl Tuğci, Alper Gezdirici, Can Berk Aşaroğlu, Ercan Atasoy, İbrahim Sayın, and Zahide Mine Yazıcı. Cochlear implantation in primrose syndrome with a novel zbtb20 gene variant. Turkish Archives of Otorhinolaryngology, 61:192-200, Dec 2024. URL: https://doi.org/10.4274/tao.2023.2023-4-5, doi:10.4274/tao.2023.2023-4-5. This article has 0 citations.
(long2023aninfantwith pages 1-2): Calista Long, Barry DeRose, Anthony B Lal, and Elizabeth Imboden. An infant with primrose syndrome: a case report. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.46546, doi:10.7759/cureus.46546. This article has 2 citations.
(melis2020primrosesyndromecharacterization pages 4-7): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.
(arora2021primrosesyndromea pages 6-8): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.
(melis2020primrosesyndromecharacterization pages 8-10): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.
(juven2020primrosesyndromea pages 1-2): Aurélien Juven, Sophie Nambot, Amélie Piton, Nolwenn Jean-Marçais, Alice Masurel, Patrick Callier, Nathalie Marle, Anne-Laure Mosca-Boidron, Paul Kuentz, Christophe Philippe, Martin Chevarin, Yannis Duffourd, Elodie Gautier, Arnold Munnich, Marlène Rio, Sophie Rondeau, Salima El Chehadeh, Élise Schaefer, Bénédicte Gérard, Sonia Bouquillon, Catherine Vincent Delorme, Christine Francannet, Fanny Laffargue, Laetitia Gouas, Bertrand Isidor, Marie Vincent, Sophie Blesson, Fabienne Giuliano, Olivier Pichon, Cédric Le Caignec, Hubert Journel, Laurence Perrin-Sabourin, Jennifer Fabre-Teste, Dominique Martin, Gaelle Vieville, Klaus Dieterich, Didier Lacombe, Anne-Sophie Denommé-Pichon, Christel Thauvin-Robinet, and Laurence Faivre. Primrose syndrome: a phenotypic comparison of patients with a zbtb20 missense variant versus a 3q13.31 microdeletion including zbtb20. European Journal of Human Genetics, 28:1044-1055, Feb 2020. URL: https://doi.org/10.1038/s41431-020-0582-3, doi:10.1038/s41431-020-0582-3. This article has 21 citations and is from a domain leading peer-reviewed journal.
(arora2021primrosesyndrome pages 6-8): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.
(li2024noveldenovo pages 5-7): Jiayi Li, Chuan Zhang, Xinyuan Tian, Bingbo Zhou, Xue Chen, Yupei Wang, Shengju Hao, Ling Hui, and Zhaoyan Meng. Novel de novo mutation in zbtb20 in a chinese primrose syndrome family and a review of the literature. Molecular Genetics & Genomic Medicine, Dec 2024. URL: https://doi.org/10.1002/mgg3.2304, doi:10.1002/mgg3.2304. This article has 1 citations and is from a peer-reviewed journal.
(arora2021primrosesyndromea pages 10-13): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.
(moon2024resolutionofsevere pages 1-2): Young Min Moon, Sa Eun Park, Constance Smith‐Hicks, and Aaron Hauptman. Resolution of severe neurobehavioral difficulties in an individual with primrose syndrome with sertraline. American Journal of Medical Genetics Part A, Mar 2024. URL: https://doi.org/10.1002/ajmg.a.63610, doi:10.1002/ajmg.a.63610. This article has 1 citations.
(stellacci2018clinicalandfunctional pages 13-16): Emilia Stellacci, Katharina Steindl, Pascal Joset, Laura Mercurio, Massimiliano Anselmi, Serena Cecchetti, Laura Gogoll, Markus Zweier, Annette Hackenberg, Gianfranco Bocchinfuso, Lorenzo Stella, Marco Tartaglia, and Anita Rauch. Clinical and functional characterization of two novel zbtb20 mutations causing primrose syndrome. Human Mutation, 39:959-964, Jul 2018. URL: https://doi.org/10.1002/humu.23546, doi:10.1002/humu.23546. This article has 21 citations and is from a domain leading peer-reviewed journal.
(long2023aninfantwith pages 6-7): Calista Long, Barry DeRose, Anthony B Lal, and Elizabeth Imboden. An infant with primrose syndrome: a case report. Cureus, Oct 2023. URL: https://doi.org/10.7759/cureus.46546, doi:10.7759/cureus.46546. This article has 2 citations.
(głowskaciemny2023roleofalphafetoprotein pages 3-4): Joanna Głowska-Ciemny, Marcin Szymanski, Agata Kuszerska, Rafał Rzepka, Constantin S. von Kaisenberg, and Rafał Kocyłowski. Role of alpha-fetoprotein (afp) in diagnosing childhood cancers and genetic-related chronic diseases. Cancers, 15:4302, Aug 2023. URL: https://doi.org/10.3390/cancers15174302, doi:10.3390/cancers15174302. This article has 34 citations.
(głowskaciemny2023roleofalphafetoprotein pages 4-6): Joanna Głowska-Ciemny, Marcin Szymanski, Agata Kuszerska, Rafał Rzepka, Constantin S. von Kaisenberg, and Rafał Kocyłowski. Role of alpha-fetoprotein (afp) in diagnosing childhood cancers and genetic-related chronic diseases. Cancers, 15:4302, Aug 2023. URL: https://doi.org/10.3390/cancers15174302, doi:10.3390/cancers15174302. This article has 34 citations.
(jones2018neurodevelopmentaldisorderassociatedzbtb20 pages 1-2): Kelly A. Jones, Yue Luo, Lynn Dukes-Rimsky, Deepak P. Srivastava, Richa Koul-Tewari, Theron A. Russell, Lauren P. Shapiro, Anand K. Srivastava, and Peter Penzes. Neurodevelopmental disorder-associated zbtb20 gene variants affect dendritic and synaptic structure. PLoS ONE, 13:e0203760, Oct 2018. URL: https://doi.org/10.1371/journal.pone.0203760, doi:10.1371/journal.pone.0203760. This article has 38 citations and is from a peer-reviewed journal.
(melis2020primrosesyndromecharacterization pages 10-11): Daniela Melis, Daniel Carvalho, Tina Barbaro‐Dieber, Alberto J. Espay, Michael J. Gambello, Blanca Gener, Erica Gerkes, Marrit M. Hitzert, Hanne B. Hove, Sandra Jansen, Petr E. Jira, Katherine Lachlan, Leonie A. Menke, Vinodh Narayanan, Damara Ortiz, Eline Overwater, Renata Posmyk, Keri Ramsey, Alessandro Rossi, Renata Lazari Sandoval, Constance Stumpel, Kyra E. Stuurman, Viviana Cordeddu, Peter Turnpenny, Pietro Strisciuglio, Marco Tartaglia, Sheela Unger, Todd Waters, Clare Turnbull, and Raoul C. Hennekam. Primrose syndrome: characterization of the phenotype in 42 patients. Clinical Genetics, 97:890-901, Apr 2020. URL: https://doi.org/10.1111/cge.13749, doi:10.1111/cge.13749. This article has 38 citations and is from a peer-reviewed journal.
(moon2024resolutionofsevere pages 2-2): Young Min Moon, Sa Eun Park, Constance Smith‐Hicks, and Aaron Hauptman. Resolution of severe neurobehavioral difficulties in an individual with primrose syndrome with sertraline. American Journal of Medical Genetics Part A, Mar 2024. URL: https://doi.org/10.1002/ajmg.a.63610, doi:10.1002/ajmg.a.63610. This article has 1 citations.
(arora2021primrosesyndrome pages 8-10): V Arora, CR Ferreira, RD Puri, and IC Verma. Primrose syndrome. Unknown journal, 2021.